Ars Technica Reports Moderna Receives Funding for Ebola Vaccine Development

Moderna has secured $50 million to accelerate the development of an mRNA Ebola vaccine against the Bundibugyo strain amid growing outbreak fears. This funding represents a significant investment in biotechnology to combat emerging viral threats. The project highlights the intersection of advanced technology and global health and security.